Zymenex’s goal is to develop a number of enzyme replacement therapies for rare diseases (present focus being on lysosomal storage disorders), which may have an Orphan Drug potential.
Its most advanced project, aiming at treating patients with alpha-Mannosidosis, is currently under regulatory review by the EMA. Two early projects are in research and preclinical stage, addressing the lysosomal disorders Krabbe Disease and Aspartylglucosaminuria.

Zymenex A/S Roskildevej 12 C
3400 Hillerød, DK
Tel  +45 48250054
Fax  +45 48251054
Affiliate Sweden Agavägen 58
181 55 Lidingö, S
Tel  +46 8 7670203
Fax  +46 8 7670233

© 2004 Zymenex A/S